FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely immunology and may be used for treating rheumatoid arthritis. That is ensured by the use of a pharmaceutical composition containing an active principle presented by a monoclonal antibody which recognises a CD6 human leukocyte differentiation antigen and produced by secreting hybridoma IOR-TIA with deposition No. ECACC 96112640, and an applicable excipient. What is also presented is a method for the use of the pharmaceutical composition in the form of injections, as well as the use of a monoclonal antibody which recognises the CD6 human leukocyte differentiation antigen, for preparing a therapeutic agent.
EFFECT: group of inventions provides a prolonged therapeutic effect in the patients suffering rheumatoid arthritis after a short period of administration.
3 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS ABLE TO INDUCE CANCER CELL APOPTOSIS FOR DIAGNOSING AND TREATING B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA | 2007 |
|
RU2454245C2 |
| ANTIBODIES TO CD6 FOR THE TREATMENT OF SEVERE ASTHMA | 2019 |
|
RU2796586C2 |
| METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
| AGENT FOR TREATING DISEASE | 2009 |
|
RU2540013C2 |
| USING ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES IN PATIENT WITH INADEQUATE RESPONSE TO TNF-ALPHA INHIBITOR | 2008 |
|
RU2489166C2 |
| TREATMENT OF AUTOIMMUNE DISEASES IN PATIENT SUFFERING FROM INADEQUATE RESPONSE TO TNF-ALPHA INHIBITOR | 2004 |
|
RU2358762C9 |
| AGENT FOR DISEASE TREATMENT | 2009 |
|
RU2540018C2 |
| MONOCLONAL ANTIBODIES AND METHODS OF USING THEM | 2017 |
|
RU2694412C2 |
| HUMANISED ANTI-BETA 9 CHAIN ANTIBODIES OF HUMAN TRBV9 TKP FAMILY, AND METHODS OF USING | 2018 |
|
RU2712251C1 |
| METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
